Abstract
While effective at preventing Zaire ebolavirus (EBOV) disease, cellular immunity to EBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing Ebola glycoprotein (rVSVΔG-EBOV-GP) vaccine remains poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies, IgG-producing memory B cells, and T cell reactivity to EBOV glycoprotein, vesicular stomatitis virus-Indiana strain (VSV-I) matrix protein, and VSV-I nucleoprotein were measured using ELISA, ELISpot, and intracellular cytokine staining, respectively. Eleven participants previously received a different investigational Ebola vaccine. All participants met positivity criteria for IgG antibodies to, and circulating IgG-producing memory B cells to, EBOV glycoprotein following rVSVΔG-EBOV-GP vaccination. Transient IgM and IgG antibody responses to VSV-I matrix protein (n=1/32 and n=0/32, respectively) and nucleoprotein (n=2/32 and n=1/32, respectively) were infrequently detected, as were IgG-producing memory B cells recognizing VSV-I matrix protein (n=3/31) and nucleoprotein (n=2/31). CD4+ and CD8+ T cell responses to EBOV glycoprotein were present in 15/32 and 19/32 participants at baseline and in 32/32 and 23/32 participants one month post-vaccination, respectively. CD4+ and CD8+ T cell responses to VSV-I matrix protein (n=17/32 and n=16/32, respectively) and VSV-I nucleoprotein (n=23/32 for both CD4+ and CD8+ responses) were common post-vaccination. T cell responses were predominantly mono-cytokine, except CD8+ responses to EBOV glycoprotein among heterologous Ebola vaccine-experienced participants and CD8+ responses to VSV-I nucleoprotein. Overall, rVSVΔG-EBOV-GP elicits robust humoral and memory B cell responses to EBOV glycoprotein in both Ebola vaccine-naïve and heterologous Ebola vaccine-experienced individuals and can generate vector-directed T cell immunity. Further research is needed to understand the significance of pre-existing vector-directed immunity on responses to booster doses of rVSVΔG-EBOV-GP and other rVSV-vectored vaccines.
Competing Interest Statement
Competing Interests: MJM received research contracts from Lilly, Pfizer, and Sanofi, and serves on advisory boards for Pfizer and Meissa Vaccines. VR received a research contract from Sanofi. NR received research contracts from Lilly, Pfizer, Merck, Quidel, and Sanofi.
Clinical Trial
NCT02788227
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [grant number T32AI074492 to V.R, N.R., and M.J.M.] and NIH/NIAID contract number HHSN272201300018I/HHSN27200021 to Emory University Vaccine and Treatment Evaluation Unit. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Emory University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author Email: Yongxian Xu: y.xu{at}emory.edu; Juliet Morales: jmoral22{at}jh.edu; Lilin Lai: llai{at}emory.edu; Nadine Rouphael: nroupha{at}emory.edu; Richard T. Davey: rdavey{at}niaid.nih.gov; Mark J. Mulligan: Mark.Mulligan{at}nyulangone.org
Funding: This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [grant number T32AI074492 to V.R, N.R., and M.J.M.] and NIH/NIAID contract number HHSN272201300018I/HHSN27200021 to Emory University Vaccine and Treatment Evaluation Unit. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.
Competing Interests: MJM received research contracts from Lilly, Pfizer, and Sanofi, and serves on advisory boards for Pfizer and Meissa Vaccines. VR received a research contract from Sanofi. NR received research contracts from Lilly, Pfizer, Merck, Quidel, and Sanofi.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- ChAd3-EBO-Z
- replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire ebolavirus glycoprotein
- EBOV
- Ebola virus
- GP
- glycoprotein
- M
- Matrix protein
- MBC
- Memory B cell
- MVA-BN-Filo
- modified vaccinia Ankara virus expression Zaire ebolavirus glycoprotein and other filovirus antigens
- NP
- Nucleoprotein
- PREPARE
- The Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zair for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure
- rVSV
- Recombinant vesicular stomatitis virus
- rVSVΔG-EBOV-GP
- Recombinant vesicular stomatitis virus Ebola vaccine
- VSV-I
- Vesicular stomatitis virus Indiana strain